|Articles|April 11, 2022
- Pharmaceutical Executive-04-01-2022
- Volume 42
- Issue 4
Pharmaceutical Executive, April 2022 Issue (PDF)
Click the title above for a link to open the Pharmaceutical Executive April 2022 issue in an interactive PDF format.
Advertisement
Articles in this issue
about 4 years ago
Seven Lessons I Learned Working at a Biotech Startupabout 4 years ago
Next-Gen Partnerships: The Ascent of Advanced Therapiesabout 4 years ago
Advantage Pharma: Capitalizing on Workforce Lessonsabout 4 years ago
Diversity in Action: Q&A With Reshma Kewalramaniabout 4 years ago
Diversity in Action: Q&A With Bob McMahonabout 4 years ago
A Dogged Devotionabout 4 years ago
Surviving Biotech’s Longest and Steepest Bear Market Everabout 4 years ago
The Case for Elevating a Brand’s Price Propositionabout 4 years ago
The Impact of Hybrid Workplace Decisions On DE&I DynamicsAdvertisement
Advertisement
Advertisement
Trending on PharmExec
1
Eli Lilly’s Foundayo and Lower-Dose Zepbound Helped Maintain Weight Loss in Patients Switching from Injectables
2
Beyond the Molecule: The New Competitive Battlefield in Oncology
3
FDA Approves Beqalzi for Relapsed or Refractory Mantle Cell Lymphoma, Inqovi in Combination with Venetoclax
4
Being an Expert Is About More Than Just Knowing the Answers
5

